|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Acquired in-process research and development | |||||
| General and administrative | |||||
| Impairment of intangible assets | |||||
| Total operating expenses | |||||
| Other operating income, net | |||||
| Operating loss | |||||
| Other income, net | |||||
| Income tax benefit | |||||
| Interest expense | |||||
| Net loss | |||||
| Net loss per share: | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted average common shares outstanding: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
| Other comprehensive income (loss): | |||||
| Foreign currency translation adjustments | |||||
| Reclassification of unrealized loss on short-term investments to other income, net | |||||
| Reclassification of cumulative currency translation gain to other income, net | |||||
| Unrealized gain on short-term investments | |||||
| Comprehensive loss | |||||
Loading...